• Yanlin Jia, Ken Chen, Peihui Lin, Gissela Lieber, Miyuki Nishi, Rosalie Yan, Zhen Wang, Yonggang Yao, Yu Li, Bryan A Whitson, Pu Duann, Haichang Li, Xinyu Zhou, Hua Zhu, Hiroshi Takeshima, John C Hunter, Robbie L McLeod, Noah Weisleder, Chunyu Zeng, and Jianjie Ma.
• Respiratory and Immunology, Merck Research Lab, Kenilworth, NJ 07033.
• Nat Commun. 2014 Jul 18; 5: 4387.

AbstractInjury to lung epithelial cells has a role in multiple lung diseases. We previously identified mitsugumin 53 (MG53) as a component of the cell membrane repair machinery in striated muscle cells. Here we show that MG53 also has a physiological role in the lung and may be used as a treatment in animal models of acute lung injury. Mice lacking MG53 show increased susceptibility to ischaemia-reperfusion and overventilation-induced injury to the lung when compared with wild-type mice. Extracellular application of recombinant human MG53 (rhMG53) protein protects cultured lung epithelial cells against anoxia/reoxygenation-induced injuries. Intravenous delivery or inhalation of rhMG53 reduces symptoms in rodent models of acute lung injury and emphysema. Repetitive administration of rhMG53 improves pulmonary structure associated with chronic lung injury in mice. Our data indicate a physiological function for MG53 in the lung and suggest that targeting membrane repair may be an effective means for treatment or prevention of lung diseases.

44 keywords...

hide…